Market Size

The target patient group for this technology is the predominantly young, active patient, who has suffered traumatic knee cartilage injury, often as a result of a sporting accident. We believe the current potential market in the USA and Europe for articular cartilage injuries is approximately 1.2 million patients annually, of which the anticipated immediately addressable market is about 500,000 patients.

There is also a substantial pool of patients that have suffered traumatic articular cartilage damage in the past and have yet to develop osteoarthritis (OA), which may also be suitable for treatment with INSTRUCT.